hit counter

Genetic (Polygenic) Risk for Psychiatric Disorders & Subject-Specific School Grades (2023 Study)

The intricate connection between mental health and educational attainment is a subject of growing interest and importance. Recent studies have shed light on how genetic predispositions to certain mental disorders can influence academic performance, challenging our understanding of how mental health impacts learning. Highlights: Polygenic Risk Scores Reveal New Insights: Studies utilizing polygenic risk scores …

Read more

Genetic Risk for Low Vitamin D Linked to Lower Social Motivation in First-Episode Psychosis (2024 Study)

Recent research reveals a notable association between vitamin D levels and the severity of negative symptoms in individuals with first-episode psychosis (FEP). A new study explored the genetic predisposition towards lower vitamin D levels and its impact on symptom severity in schizophrenia and related disorders. Highlights: Vitamin D & Psychosis Connection: Lower levels of vitamin …

Read more

Probiotics & Synbiotics for the Metabolic Side Effects of Psychiatric Medications: Are They Effective? (2024 Review)

Patients with severe mental illnesses (SMI), such as schizophrenia and chronic depression, often face the challenge of managing weight gain and metabolic complications, side effects commonly associated with antipsychotics and antidepressants. These medications are known to induce increased appetite and weight gain, leading to long-term metabolic syndromes. Recent studies have evaluated into the role of …

Read more

MicroRNA Biomarkers May Help Diagnose Schizophrenia

Schizophrenia (SZ) is a complex psychiatric disorder characterized by a myriad of symptoms, typically divided into positive, negative, and cognitive categories. Despite the prevalence and severity of this condition, current diagnostic methods are largely based on subjective clinical interviews and observations, leading to potential misdiagnosis and delayed treatment. Recent studies have focused on microRNAs (miRNAs) …

Read more

BPC-157 Peptide for Neurological & CNS Disorders: Preliminary Research

BPC 157, a stable gastric pentadecapeptide, has recently emerged as a promising therapeutic agent due to its multifaceted role in treating various central nervous system disorders. Its ability to mitigate conditions like stroke, schizophrenia, and spinal cord injuries while promoting neural recovery and functional improvement is capturing the interest of the medical community. Highlights: BPC …

Read more

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder.  In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient.  The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

Read more

20+ New Schizophrenia Medications In Development (2015)

It is estimated that over 2.5 million adults in the United States have been diagnosed with schizophrenia; this equates to approximately 1.1% of the population.  There are many different types of schizophrenia, in fact, genetic clusters suggest it is 8 distinct diseases.  Therefore not everyone diagnosed with schizophrenia has the same set of symptoms. Certain …

Read more